DAVENPORT & Co LLC acquired a new stake in Bellerophon Therapeutics Inc (NASDAQ:BLPH) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 107,150 shares of the biotechnology company’s stock, valued at approximately $1,345,000. DAVENPORT & Co LLC owned 1.13% of Bellerophon Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also bought and sold shares of BLPH. Renaissance Technologies LLC lifted its holdings in shares of Bellerophon Therapeutics by 7.8% in the fourth quarter. Renaissance Technologies LLC now owns 1,679,303 shares of the biotechnology company’s stock valued at $587,000 after purchasing an additional 121,500 shares in the last quarter. Credit Agricole S A purchased a new stake in shares of Bellerophon Therapeutics in the first quarter valued at about $35,000. Finally, Morgan Stanley lifted its holdings in shares of Bellerophon Therapeutics by 426.6% in the first quarter. Morgan Stanley now owns 2,633 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 2,133 shares in the last quarter. Institutional investors own 19.15% of the company’s stock.
Shares of BLPH opened at $12.84 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.34 and a quick ratio of 1.34. The company’s 50 day simple moving average is $13.06 and its 200 day simple moving average is $10.27. Bellerophon Therapeutics Inc has a 1 year low of $3.19 and a 1 year high of $26.00.
Bellerophon Therapeutics (NASDAQ:BLPH) last announced its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.13. Sell-side analysts predict that Bellerophon Therapeutics Inc will post -1.79 earnings per share for the current year.
Several analysts have issued reports on BLPH shares. Brookline Capital Management started coverage on shares of Bellerophon Therapeutics in a report on Tuesday, April 14th. They issued a “buy” rating and a $35.00 price target on the stock. ValuEngine downgraded shares of Bellerophon Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, May 1st. Finally, Maxim Group reissued a “buy” rating and set a $30.00 price objective on shares of Bellerophon Therapeutics in a research note on Thursday, May 14th.
Bellerophon Therapeutics Profile
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.
Further Reading: Is a Roth IRA right for you?
Want to see what other hedge funds are holding BLPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bellerophon Therapeutics Inc (NASDAQ:BLPH).
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.